Article
Large database reveals surprises in mCRPC management
Analysis of a large, real-world patient database reveals interesting findings about the current management of metastatic castration-resistant prostate cancer, including a few surprises. Celestia Higano, MD, said 77% of patients received first-line therapy.
Analysis of a large, real-world patient database reveals interesting findings about the current management of metastatic castration-resistant prostate cancer, including a few surprises.
Celestia Higano, MD, of the University of Washington School of Medicine, Seattle, said 77% of patients received first-line therapy.
“Only about 60% of the patients received any kind of so-called bone health agent, meaning either denosumab or zoledronic acid, which is rather odd since the [NCCN] guidelines clearly recommend that those be used unless there is an absolute contraindication,” Dr. Higano said in this Urology Times video interview, conducted at the Genitourinary Cancers Symposium in San Francisco.
Dr. Higano also discusses the use of docetaxel and trends in back-to-back use of newer antiandrogen therapies in this patient population.
Dr. Higano has a leadership position with and stock/other ownership interests in CTI; receives honoraria from Genentech; and has a consulting/advisory role with Astellas Pharma, Bayer, Blue Earth Diagnostics, Clovis Oncology, Ferring, Hinova, Janssen, Myriad Genetics, Orion Corp., and Tolmar.
